CohBar Entered into Definitive Merger Agreement with Morphogenesis to Advance Late-Stage Oncology Candidates
- CohBar shareholders will receive a dividend of 3.30 shares of CohBar common stock & pre-merger CohBar shareholders will receive a CVR related to the disposition of any of its assets for 3yrs. The transaction is expected to close in Q3’23
- The pre-merger CohBar equity holders will own ~15%; pre-merger Morphogenesis equity holders will own ~77% of the new company on a pro forma basis & investors would own ~9%. The combined company will operate under the name “TuHURA Biosciences, Inc” & will trade on Nasdaq, advancing a personalized cancer vaccine platform & preclinical tumor microenvironment modulator
- The P-II/III study of IFx-Hu2.0 is expected to initiate in 2024. CohBar entered into a stock purchase agreement with an affiliate of an investor in Morphogenesis for a $15M private placement to advance the new company’s pipeline, providing a cash runway through 2024
Ref: Globe Newswire | Image: CohBar
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at [email protected]
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].